ROCKVILLE, Md., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage
biopharmaceutical company developing next generation therapeutics for the treatment of cancer, announced today that Peter D.
Suzdak, Ph.D., the Company’s Chief Executive Officer, will be presenting at the 9th Annual Biotech Showcase™ 2017
conference.
Dr. Suzdak is scheduled to present at 8:30 a.m. PST on Tuesday, January 10, 2017, in Room 7 (Ballroom Level) at
the Hilton San Francisco Union Square, 333 O’Farrell St, San Francisco, CA. An audio webcast of the presentation will be available
on the Company's website at www.rexahn.com in the Investor Relations section
under 'Events and Presentations'.
About Rexahn Pharmaceuticals, Inc.
Rexahn Pharmaceuticals Inc. (NYSE MKT:RNN) is a clinical stage biopharmaceutical company dedicated to developing
novel, best-in-class therapeutics for the treatment of cancer. The Company’s mission is to improve the lives of cancer
patients by developing next generation cancer therapies that are designed to maximize efficacy while minimizing the toxicity and
side effects traditionally associated with cancer treatment. Rexahn’s product candidates work by targeting and neutralizing
specific proteins believed to be involved in the complex biological cascade that leads to cancer cell growth. Pre-clinical studies
show that certain of Rexahn’s product candidates may be effective against multiple types of cancer, drug resistant cancers, and
difficult-to-treat cancers, and others may augment the effectiveness of current FDA-approved cancer treatments. The Company
has a broad oncology pipeline that includes three anti-cancer compounds currently in clinical development: Supinoxin; RX-3117; and
Archexin®, and a novel nanopolymer-based drug delivery platform technology that may increase the bio-availability of
FDA-approved chemotherapies. For more information about the Company and its oncology programs, please visit www.rexahn.com.
Safe Harbor
To the extent any statements made in this press release deal with information that is not historical, these are
forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited
to, statements about Rexahn’s plans, objectives, future operations and products, enrollments in clinical trials, the path of
clinical trials and development activities, anticipated market sizes, and other statements identified by words such as “will,”
“potential,” “could,” “can,” “believe,” “intends,” “continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,” other words
of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different
degrees, uncertain. Uncertainties and risks may cause Rexahn’s actual results to be materially different than those expressed in or
implied by Rexahn’s forward-looking statements. For Rexahn, particular uncertainties and risks include, among others, the
difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; that
the early or potential evidence in a clinical trial will not reflect the complete results of the trial; that results of preclinical
studies and earlier stage clinical trials may not be predictive of the results of later-stage clinical trials; the success and
design of clinical testing; and Rexahn’s need for and ability to obtain additional financing. More detailed information on these
and additional factors that could affect Rexahn’s actual results are described in Rexahn’s filings with the Securities and Exchange
Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking
statements in this news release speak only as of the date of this news release. Rexahn undertakes no obligation to update or revise
any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact: LifeSci Advisors, LLC Matthew P. Duffy (212) 915-0685 matthew@lifesciadvisors.com